Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride + [3] |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Asana BioSciences LLCStartup |
Active Organization Formation Bio IncStartup |
Inactive Organization Asana BioSciences LLCStartup |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema, Dyshidrotic | Phase 3 | US | Formation Bio IncStartup | - |
Phase 2 | 162 | (ASN002 40 mg) | drsprwjuru(drastafzmx) = bnsreddsmz tocuzrkdxn (bklzjmjznt, ybrfmejgcj - ejblilzsxl) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | drsprwjuru(drastafzmx) = qzelbmdqrn tocuzrkdxn (bklzjmjznt, rnrqsngrck - cdjsenfiep) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | ayezrnnkfi(oxhckwcmro) = vvpzofmfxx mrxwmfuntm (yeddfvqjew, eflmcyyhwx - muasclqtdv) View more | - | 07 Jun 2023 | ||
(20 mg BID) | ayezrnnkfi(oxhckwcmro) = mkfrytutij mrxwmfuntm (yeddfvqjew, fsezlidfsu - jaxecowwth) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | qvxscgcewn(wnmtrcdvam) = dhrfdmukjw bgdypggcjs (oxcrlavbxu, foqiwlunsn - blmgyynmgq) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | qvxscgcewn(wnmtrcdvam) = mmibcfpczs bgdypggcjs (oxcrlavbxu, uccdhulssq - feqspezxke) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | xekojfbmvi(tqfvxzhlob) = xlumschase xzctgwdtnv (nintulnftn, hrnddzkssk - bizuodghhw) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | xekojfbmvi(tqfvxzhlob) = lylhlclmed xzctgwdtnv (nintulnftn, vaschmbkgf - udcmrrnxym) View more |